Avidity Biosciences

company

About

Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.

Details

Last Funding Type
Series B
Last Funding Money Raised
$16M
Industries
Biotechnology,Health Care,Life Science,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:RNA
Legal Name
Avidity Biosciences, Inc

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$645.16M
Avidity Biosciences has raised a total of $645.16M in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 15, 2022 Post-IPO Equity $207M Detail
Jun 11, 2020 IPO $298.10M Detail
Nov 13, 2019 Series C $100M 10 RTW Investments Detail
Apr 22, 2019 Series Unknown $15M 1 Eli Lilly Detail
Oct 17, 2018 Series B $16M 8 Takeda Detail

Investors

Number of Lead Investors
Number of Investors
4
17
Avidity Biosciences is funded by 17 investors. RTW Investments and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
RTW Investments Yes Series C
Takeda Yes Series B
Eight Roads Ventures Yes Series Unknown
Alethea Capital Management Series C
Brace Pharma Series C
Cormorant Asset Management Series C
CureDuchenne Ventures Series C
Eli Lilly Series C
Logos Capital Series C
Partner Fund Management Series C

Employee Profiles

Number of Employee Profiles
8
Avidity Biosciences has 8 current employee profiles, including Executive Arthur Levin
Executive
Board member
Executive
Executive
Executive